| scholarly article | Q13442814 |
| P50 | author | Bradley Hyman | Q23303113 |
| Rebecca Betensky | Q42290664 | ||
| Aaron P. Schultz | Q55127291 | ||
| Jorge Sepulcre | Q56826828 | ||
| Reisa Sperling | Q56862977 | ||
| Teresa Gómez-Isla | Q89680092 | ||
| Rebecca E. Amariglio | Q109557561 | ||
| P2093 | author name string | Mark Albers | |
| Keith A Johnson | |||
| Dorene Rentz | |||
| J Alex Becker | |||
| Neil Vasdev | |||
| Gad Marshall | |||
| Jasmeer Chhatwal | |||
| Bradford Dickerson | |||
| Daniel Yokell | |||
| Elizabeth Mormino | |||
| Jonathan Alverio | |||
| Kate Papp | |||
| Kelly Judge | |||
| Lesley Pepin | |||
| Marlie Philiossaint | |||
| Samantha Mauro | |||
| Timothy Shoup | |||
| P2860 | cites work | “Mini-mental state” | Q25938989 |
| Tau imaging: early progress and future directions | Q28253740 | ||
| Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 | ||
| The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 | ||
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Development and validation of a geriatric depression screening scale: a preliminary report | Q29615638 | ||
| The Clinical Dementia Rating (CDR): current version and scoring rules | Q29616280 | ||
| Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease | Q29617286 | ||
| Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. | Q30378181 | ||
| Disruption of functional connectivity in clinically normal older adults harboring amyloid burden | Q30492809 | ||
| Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease | Q33672569 | ||
| Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects | Q34356874 | ||
| Primary age-related tauopathy (PART): a common pathology associated with human aging | Q34445021 | ||
| Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry | Q34556945 | ||
| National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Q34635272 | ||
| Tau aggregation in the hippocampal formation: an ageing or a pathological process? | Q35019484 | ||
| Amyloid-β associated cortical thinning in clinically normal elderly | Q35053524 | ||
| Subjective cognitive complaints and amyloid burden in cognitively normal older individuals | Q36322792 | ||
| Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature | Q36575903 | ||
| Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center | Q37656915 | ||
| In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. | Q38436447 | ||
| A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807 | Q42253028 | ||
| Frequency of stages of Alzheimer-related lesions in different age categories | Q42445469 | ||
| [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease | Q42712929 | ||
| Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology | Q43467553 | ||
| Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. | Q45810537 | ||
| [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies | Q48342095 | ||
| Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease | Q48442778 | ||
| Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study | Q48455136 | ||
| Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. | Q48963534 | ||
| Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. | Q50620222 | ||
| Sequence-independent segmentation of magnetic resonance images. | Q51985867 | ||
| P433 | issue | 1 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 110-119 | |
| P577 | publication date | 2015-10-27 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Tau positron emission tomographic imaging in aging and early Alzheimer disease | |
| P478 | volume | 79 |
| Q46616293 | 18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study |
| Q41600997 | 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease |
| Q55359027 | 18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. |
| Q37739887 | 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. |
| Q37198563 | 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers |
| Q53396939 | 18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. |
| Q39270980 | A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies |
| Q64124512 | A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology |
| Q57927766 | A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer's Disease |
| Q37590389 | A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease |
| Q92504733 | A circuit view of deep brain stimulation in Alzheimer's disease and the possible mechanisms |
| Q39434968 | A clinicopathological approach to the diagnosis of dementia |
| Q92477551 | A longitudinal model for tau aggregation in Alzheimer's disease based on structural connectivity |
| Q90140035 | A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia |
| Q58778649 | A novel partial volume correction method for accurate quantification of [F] flortaucipir in the hippocampus |
| Q90246734 | A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease |
| Q64245708 | A walk through tau therapeutic strategies |
| Q26745508 | A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers |
| Q40239437 | AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy |
| Q90246320 | APOEε4 potentiates the relationship between amyloid-β and tau pathologies |
| Q38653494 | AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure |
| Q37633577 | AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies |
| Q90157800 | Aberrant brain network connectivity in presymptomatic and manifest Huntington's disease: A systematic review |
| Q90198060 | Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development |
| Q53397162 | Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. |
| Q38812890 | Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study |
| Q38675107 | Alzheimer Disease: Scientific Breakthroughs and Translational Challenges |
| Q88503397 | Alzheimer disease: Preclinical Alzheimer disease - the new frontier |
| Q90602927 | Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention |
| Q88755570 | Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease |
| Q83225104 | Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity |
| Q92315625 | Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age |
| Q46357983 | Amyloid deposition in younger adults is linked to episodic memory performance. |
| Q57159910 | Amyloid-associated increases in longitudinal report of subjective cognitive complaints |
| Q89751795 | Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity |
| Q91526804 | Amyloid-β-independent regulators of tau pathology in Alzheimer disease |
| Q55146345 | An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. |
| Q37096748 | An Alzheimer's Disease Genetic Risk Score Predicts Longitudinal Thinning of Hippocampal Complex Subregions in Healthy Older Adults |
| Q40118660 | Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration |
| Q58724364 | Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice |
| Q48276843 | Apolipoprotein-E (Apoe) ε4 and cognitive decline over the adult life course |
| Q64107058 | Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies |
| Q90104103 | Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment |
| Q39135327 | Approach to atypical Alzheimer's disease and case studies of the major subtypes. |
| Q57214180 | Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging |
| Q50051841 | Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease |
| Q37600680 | Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study |
| Q92083003 | Association between Brain and Plasma Glutamine Levels in Healthy Young Subjects Investigated by MRS and LC/MS |
| Q46158333 | Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals |
| Q64900616 | Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. |
| Q48290101 | Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease |
| Q45974423 | Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease. |
| Q91615306 | Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum |
| Q64261095 | Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease |
| Q92843396 | Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia |
| Q64106160 | Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue |
| Q64952063 | Biomarkers for tau pathology. |
| Q38979999 | Biomarkers for the Early Detection and Progression of Alzheimer's Disease |
| Q92621402 | Biomarkers for the diagnosis of Alzheimer's disease, dementia Lewy body, frontotemporal dementia and vascular dementia |
| Q92898110 | Biomarkers in Alzheimer's, Frontotemporal, Lewy Body, and Vascular Dementias |
| Q39413097 | Biomarkers in Neurodegenerative Diseases |
| Q91268052 | Biomedical informatics applications for precision management of neurodegenerative diseases |
| Q30275833 | Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy |
| Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
| Q26769952 | Characteristics of Tau and Its Ligands in PET Imaging |
| Q47739900 | Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau. |
| Q39440179 | Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases |
| Q33563786 | Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance |
| Q47658947 | Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease |
| Q38739937 | Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease |
| Q90214060 | Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology |
| Q64111267 | Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging |
| Q55003313 | Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology. |
| Q38640294 | Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. |
| Q58120970 | Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease |
| Q91642301 | Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults |
| Q38803637 | Defining imaging biomarker cut points for brain aging and Alzheimer's disease |
| Q64298179 | Dementia spectrum disorders: lessons learnt from decades with PET research |
| Q38659171 | Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study |
| Q58099840 | Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [F]Flortaucipir PET |
| Q93055003 | Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions |
| Q90263999 | Differential Associations Between Volumes of Atrophic Cortical Brain Regions and Memory Performances in Early and Late Mild Cognitive Impairment |
| Q57493164 | Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders |
| Q58794612 | Disease-related patterns of in vivo pathology in Corticobasal syndrome |
| Q90725338 | Dissociation of Tau Deposits and Brain Atrophy in Early Alzheimer's Disease: A Combined Positron Emission Tomography/Magnetic Resonance Imaging Study |
| Q46142950 | Distinct Phases of Tau, Amyloid, and Functional Connectivity in Healthy Older Adults. |
| Q48729466 | Distinct tau PET imaging patterns in typical and atypical Alzheimer's disease |
| Q38383420 | Distinct white matter injury associated with medial temporal lobe atrophy in Alzheimer's versus semantic dementia |
| Q62779168 | Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain |
| Q38933111 | Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. |
| Q92402592 | Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span |
| Q46766203 | Elevated 18F-AV-1451 PET tracer uptake detected in incidental imaging findings |
| Q54737738 | Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. |
| Q55311648 | Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. |
| Q45870549 | Emerging Diagnostic and Therapeutic Strategies for Tauopathies |
| Q46075858 | Entorhinal tau pathology, episodic memory decline and neurodegeneration in aging. |
| Q64965222 | Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain. |
| Q99628399 | Evaluation of Imaging Windows for Tau PET Imaging Using 18F-PI2620 in Cognitively Normal Individuals, Mild Cognitive Impairment, and Alzheimer's Disease Patients |
| Q42330310 | Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy |
| Q60946653 | Evaluation of the Feasibility of Screening Tau Radiotracers Using an Amyloid Biomathematical Screening Methodology |
| Q64115558 | F-Flortaucipir in TDP-43 associated frontotemporal dementia |
| Q61804682 | F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes |
| Q47684719 | Flortaucipir tau PET imaging in semantic variant primary progressive aphasia |
| Q48284478 | Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline |
| Q87865855 | Following the pathway to Alzheimer's disease |
| Q46677826 | Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations |
| Q91635608 | Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease |
| Q31162702 | Future Directions in Imaging Neurodegeneration |
| Q90707233 | Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948 |
| Q30100986 | Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex |
| Q91961758 | Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships |
| Q39373058 | Hippocampal shape alterations are associated with regional Aβ load in cognitively normal elderly individuals |
| Q90732164 | Human non-REM sleep and the mean global BOLD signal |
| Q50650775 | Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach. |
| Q50044294 | Imaging Alzheimer's disease pathophysiology with PET. |
| Q60950130 | Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review |
| Q93265075 | Imaging biomarkers in neurodegeneration: current and future practices |
| Q37063163 | Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm |
| Q49957645 | Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions |
| Q91860896 | Imaging the evolution and pathophysiology of Alzheimer disease |
| Q88732357 | In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls |
| Q47199611 | In Vivo Comparison of Tau Radioligands 18F-THK-5351 and 18F-THK-5317. |
| Q37096041 | In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain |
| Q48687926 | In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. |
| Q48665805 | In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum |
| Q54942198 | Increased Uptake of AV-1451 in a Subacute Infarction Lesion. |
| Q92221525 | Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set |
| Q61804684 | Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease |
| Q91899824 | Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience |
| Q47141267 | Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. |
| Q50422287 | Joint associations of β-amyloidosis and cortical thickness with cognition |
| Q36970036 | Labeling Pathological Tau: An Important Quest for the Unknown |
| Q55254017 | Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias. |
| Q42672461 | Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case |
| Q46682283 | Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease |
| Q47658024 | Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults |
| Q92521930 | Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults |
| Q50531762 | Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake. |
| Q50583370 | Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. |
| Q51763159 | Longitudinal tau PET in ageing and Alzheimer's disease. |
| Q50061690 | MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([(18)F]-AV-1451) Binding. |
| Q38746445 | Mapping Neurodegenerative Disease Onset and Progression |
| Q51305325 | Mild Cognitive Impairment. |
| Q89918248 | Modelling prognostic trajectories of cognitive decline due to Alzheimer's disease |
| Q38836004 | Molecular and cellular pathophysiology of preclinical Alzheimer's disease |
| Q55031324 | Molecular imaging: What is right and what is an illusion? |
| Q37731710 | Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain |
| Q39346750 | Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias |
| Q47659524 | Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET. |
| Q52589491 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. |
| Q90095665 | Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention |
| Q38705770 | Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation |
| Q38911065 | Neurofibrillary Tangle Stage and the Rate of Progression of Alzheimer Symptoms: Modeling Using an Autopsy Cohort and Application to Clinical Trial Design |
| Q58105827 | Neurogenetic contributions to amyloid beta and tau spreading in the human cortex |
| Q46830566 | Neuroimaging and other modalities to assess Alzheimer's disease in Down syndrome. |
| Q55494083 | Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. |
| Q93242548 | Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers |
| Q41318515 | On the path to 2025: understanding the Alzheimer's disease continuum |
| Q46566966 | PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). |
| Q38628805 | PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers |
| Q89642986 | PET and SPECT imaging of the brain: a review on the current status of nuclear medicine in Japan |
| Q51766173 | PET imaging of tau protein targets: a methodology perspective. |
| Q59544083 | PET staging of amyloidosis using striatum |
| Q37718557 | PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease |
| Q90658867 | Parametric methods for [18F]flortaucipir PET |
| Q64062247 | Pathological Tau From Alzheimer's Brain Induces Site-Specific Hyperphosphorylation and SDS- and Reducing Agent-Resistant Aggregation of Tau |
| Q48389127 | Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies |
| Q89945308 | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg |
| Q37677783 | Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects. |
| Q38896981 | Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals |
| Q47279644 | Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy |
| Q103028221 | Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals |
| Q64064010 | Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease |
| Q64255065 | Positron emission tomography of tau in Iraq and Afghanistan Veterans with blast neurotrauma |
| Q31063014 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. |
| Q47842309 | Predicting progression from normal cognition to mild cognitive impairment for individuals at 5 years |
| Q91882184 | Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework |
| Q99615853 | Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer's disease |
| Q92707326 | Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study |
| Q40259674 | Quantification of Tau Load Using [(18)F]AV1451 PET. |
| Q64099249 | Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease |
| Q64993260 | Quantitative 18F-AV1451 Brain Tau PET Imaging in Cognitively Normal Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease Patients. |
| Q59844929 | Quantitative evaluation of tau PET tracers F-THK5351 and F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization |
| Q91963043 | Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research |
| Q47945043 | Recent advances in longitudinal structural neuroimaging of younger-onset dementias |
| Q49310065 | Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease |
| Q39429271 | Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging. |
| Q47607239 | Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden |
| Q61452943 | Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia |
| Q37294936 | Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease |
| Q60301491 | Regional tau pathology and loneliness in cognitively normal older adults |
| Q37739881 | Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition |
| Q37645272 | Repetitive head impact exposure and later-life plasma total tau in former National Football League players. |
| Q78878862 | Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report |
| Q90124620 | Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimer's Disease |
| Q47386703 | SPARCL1 Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging |
| Q36415014 | Screening for mild cognitive impairment: If not now, when? |
| Q92885959 | Sequential amyloid-β and tau accumulation foreshadows cognitive decline |
| Q60637417 | Sex differences in Alzheimer disease — the gateway to precision medicine |
| Q92088894 | Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes |
| Q92825260 | Sleep as a Potential Biomarker of Tau and β-Amyloid Burden in the Human Brain |
| Q47926474 | Small-molecule PET Tracers for Imaging Proteinopathies |
| Q57173226 | Spatial navigation deficits - overlooked cognitive marker for preclinical Alzheimer disease? |
| Q47099501 | Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer's disease subjects: an exploratory study |
| Q34682521 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers |
| Q48102802 | Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals |
| Q64054848 | Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models |
| Q45204800 | Targeting tau protein in Alzheimer's disease |
| Q62492915 | Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity |
| Q39016306 | Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials |
| Q64970016 | Tau PET With 18F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation. |
| Q91011085 | Tau PET imaging in neurodegenerative tauopathies-still a challenge |
| Q34680852 | Tau PET imaging: present and future directions |
| Q37220632 | Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. |
| Q46634925 | Tau PET: the next frontier in molecular imaging of dementia |
| Q37731919 | Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks |
| Q48409075 | Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease |
| Q39365272 | Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases |
| Q49295547 | Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. |
| Q48234728 | Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain |
| Q41700392 | Tau and β-Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging. |
| Q47886903 | Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. |
| Q64071535 | Tau covariance patterns in Alzheimer's disease patients match intrinsic connectivity networks in the healthy brain |
| Q90950184 | Tau deposition is associated with functional isolation of the hippocampus in aging |
| Q42501180 | Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy |
| Q46008245 | Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. |
| Q55416644 | Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. |
| Q47987344 | Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum |
| Q49900567 | Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech |
| Q38990773 | Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition |
| Q38633337 | Tau-imaging in neurodegeneration |
| Q64226661 | Tauopathy in veterans with long-term posttraumatic stress disorder and traumatic brain injury |
| Q39544835 | Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly |
| Q93018917 | The "rights" of precision drug development for Alzheimer's disease |
| Q41269558 | The Abnormality of Topological Asymmetry between Hemispheric Brain White Matter Networks in Alzheimer's Disease and Mild Cognitive Impairment |
| Q89217982 | The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials |
| Q49322919 | The association between tau PET and retrospective cortical thinning in clinically normal elderly |
| Q90006715 | The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes |
| Q56594907 | The development and validation of tau PET tracers: current status and future directions |
| Q63101708 | The elusive tau molecular structures: can we translate the recent breakthroughs into new targets for intervention? |
| Q42701971 | The emerging role of PET imaging in dementia. |
| Q90484535 | The impact of amyloid-beta and tau on prospective cognitive decline in older individuals |
| Q42407156 | The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging |
| Q39004340 | The road to restoring neural circuits for the treatment of Alzheimer's disease |
| Q37566888 | Therapy and clinical trials in frontotemporal dementia: past, present, and future |
| Q33695122 | Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease |
| Q55463444 | Topographic staging of tau positron emission tomography images. |
| Q93087930 | Topographical Heterogeneity of Alzheimer's Disease Based on MR Imaging, Tau PET, and Amyloid PET |
| Q33704278 | Tumor necrosis factor α Inhibition for Alzheimer's Disease |
| Q26739091 | Untangling tau imaging |
| Q90628286 | Vascular Risk and β-Amyloid Are Synergistically Associated with Cortical Tau |
| Q92753661 | Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy |
| Q64990217 | What Happens with the Circuit in Alzheimer's Disease in Mice and Humans? |
| Q47330246 | Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia |
| Q57192742 | Widespread distribution of tauopathy in preclinical Alzheimer's disease |
| Q91409433 | Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma |
| Q48261458 | [18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease |
| Q41350096 | [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy |
| Q87934114 | [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation |
| Q47252490 | [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. |
| Q96950742 | [18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease |
| Q47694602 | [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging |
| Q42360584 | [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than "off-target" binding |
| Q89146131 | [The importance of molecular imaging (PET) in the diagnostics of dementia] |
| Q92140077 | [¹⁸F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment |
| Q48254051 | cGMP production of the radiopharmaceutical [18 F]MK-6240 for PET imaging of human neurofibrillary tangles |
| Q64261988 | rs242557 variant is associated with hippocampus tau uptake on F-AV-1451 PET in non-demented elders |
Search more.